ABOS
MaterialsAcumen Pharmaceuticals Inc
$2.57+0.05 (+1.98%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ABOS Today?
No stock-specific AI insight has been generated for ABOS yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$186M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume264K
Avg Volume (10D)—
Shares Outstanding72.2M
ABOS News
20 articles- Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care ConferenceYahoo Finance·May 7, 2026
- Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026Yahoo Finance·May 5, 2026
- Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerYahoo Finance·Mar 31, 2026
- Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Mar 30, 2026
- Acumen Pharmaceuticals, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 27, 2026
- Acumen Pharmaceuticals Inc (ABOS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ...Yahoo Finance·Mar 26, 2026
- Acumen Pharmaceuticals Q4 Earnings Call HighlightsMarketbeat·Mar 26, 2026
- Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business HighlightsYahoo Finance·Mar 26, 2026
- Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026Yahoo Finance·Mar 19, 2026
- Acumen Pharmaceuticals Spotlights Sabirnetug Phase II Progress, JCR Brain-Delivery Partnership at ConferenceMarketbeat·Mar 19, 2026
- Acumen Pharma Presents Brain Delivery Studies at Alzheimer’s and Parkinson’s Diseases Conference 2026Yahoo Finance·Mar 17, 2026
- Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026Yahoo Finance·Mar 17, 2026
- Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery PortfolioYahoo Finance·Mar 16, 2026
- Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS ForumYahoo Finance·Mar 10, 2026
- Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026Yahoo Finance·Mar 3, 2026
- Assessing Acumen Pharmaceuticals (ABOS) Valuation After New Phase 2 ALTITUDE-AD Trial DevelopmentsYahoo Finance·Jan 28, 2026
- Does Sabirnetug’s Phase 2 Extension and Insider Stock Sales Alter the Bull Case for ABOS?Yahoo Finance·Jan 26, 2026
- Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny StocksYahoo Finance·Jan 25, 2026
- January 2026's Rising Stars: Top Penny Stocks To WatchYahoo Finance·Jan 19, 2026
- Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceYahoo Finance·Dec 2, 2025
All 20 articles loaded
Price Data
Open$2.54
Previous Close$2.52
Day High$2.62
Day Low$2.52
52 Week High—
52 Week Low—
Fundamentals
Market Cap$186M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume264K
Avg Volume (10D)—
Shares Outstanding72.2M
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—